Medical cannabis for psychiatric disorders

Medical cannabis for psychiatric disorders

Over last few years researchers’ attention has been focused on use of medical cannabis due to global regulatory loosening. This fact significantly increased cannabinoid therapeutics analytical data in psychiatric field. Many of them suggest that cannabinoid might improve depressive disorders and symptoms, anxiety disorders, attention-deficit hyperactivity disorder, Tourette syndrome, post-traumatic stress disorder, or psychosis. Moreover,…

Cannabis – from hippie drug to medical hype (SRF, 25.04.2022)
| | | |

Cannabis – from hippie drug to medical hype (SRF, 25.04.2022)

The SRF documentary on Medical Cannabis provides an overview on the current market situation Key takeouts: good results on patients using the medicine high prices for patient due to 1 company dominant position flowers are not yet available as medicine (it will only be available with the #pilotprojects medical Cannabis still need to evolve from…

Cannabinoids in the Treatment of Epilepsy
|

Cannabinoids in the Treatment of Epilepsy

Epilepsy is one of the most common non-transmissible neurological diseases. It is defined as a brain disorder that predisposes to seizures and has associated physical, psychological and social consequences. Approximately one-third of patients with epilepsy have seizures that are resistant to antiepileptic medications. These patients do not respond well to the conventional antiepileptic drugs. Moreover,…

Analysis of the General decision of the Swiss Chemicals Notification Authority concerning the placing on the market of perfume oil containing CBD

Analysis of the General decision of the Swiss Chemicals Notification Authority concerning the placing on the market of perfume oil containing CBD

March 24th 2022 – General decision of the Swiss Chemicals Notification Authority concerning the placing on the market of fragrances / perfume oil containing CBD, pursuant to Art. 10 (1) and (2) in connection with Art. 1 (1) to (3) of the Pest Control Products Act. A Federal decision on banning CBD from fragrances (chemical…

Medical cannabis available by prescription
|

Medical cannabis available by prescription

Starting this summer, it will be easier to get a prescription for medical cannabis. But watch your wallet, because it won’t be automatically reimbursed. Cannabis-based medicines will soon be available by prescription, without the need for exceptional authorization from the Federal Office of Public Health (FOPH). This legislative change will probably come into force in…

Analysis of the Swiss chemists’ statement saying most CBD cannabis products fail to meet standards. However, it only concerns food and veterinary products.
| |

Analysis of the Swiss chemists’ statement saying most CBD cannabis products fail to meet standards. However, it only concerns food and veterinary products.

On February 1st 2022, the Swiss Association of Cantonal Chemists, announced in a press release that, in Switzerland, the vast majority of products sold containing the cannabis extract cannabidiol (CBD) do not meet legal requirements. It was relayed across many media channels, such as swissinfo stating that Most CBD cannabis products fail to meet standards. However, these findings do not apply to the medical/therapeutic cannabis.

Analysis of the new publication regarding cannabis compound CBD stopping coronavirus.
|

Analysis of the new publication regarding cannabis compound CBD stopping coronavirus.

Several recent laboratory studies of cannabidiol, or CBD, have shown promising results in the context of prevention the coronavirus infection.  The study performed by the team of Marsha Rosner of the University of Chicago (USA) recently published evidence that CBD could block the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) responsible for COVID-19.   Their study published…

Analysis of the publication showing that cannabinoids prevent coronavirus-2 (SARS-CoV 2) infection
|

Analysis of the publication showing that cannabinoids prevent coronavirus-2 (SARS-CoV 2) infection

Content of the publication:   A new study regarding the prevention of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection responsible for COVID-19 was published on January 10, 2022, in the scientific journal “The Journal of Natural Products”[1].  Researchers from the Oregon Health and Science University in Portland (USA) have demonstrated the potential of cannabinoids to…

Implementing ordinance for facilitated access to treatments with medicinal cannabis in the consultation process
|

Implementing ordinance for facilitated access to treatments with medicinal cannabis in the consultation process

Bern, 25.08.2021 – At its meeting on August 25, 2021, the Federal Council opened the consultation on the implementation of the amendment to the Narcotics Act (BetmG) passed by Parliament. The amendment is intended to facilitate access to treatments with therapeutic cannabis. In the future, a prescription will no longer require the granting of an exceptional authorization from the Federal Office of Public Health (FOPH). Cannabis for consumption purposes, on the other hand, will continue to be prohibited.

Medical Cannabis & Cannabinoid Regulation 2021

Medical Cannabis & Cannabinoid Regulation 2021

Trends and Developments The current regulatory environment surrounding cannabinoid-based products in Switzerland is unfortunately still marked by a high degree of uncertainty, due both to vague legislative requirements and heterogenous, sometimes arbitrary, enforcement. However, with the rise of public awareness of the general benefits of the cannabis plant as a result of the cannabidiol (CBD)…